<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481219</url>
  </required_header>
  <id_info>
    <org_study_id>MA-205</org_study_id>
    <nct_id>NCT02481219</nct_id>
  </id_info>
  <brief_title>Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure</brief_title>
  <official_title>COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the optimal bowel preparation regimen for PillCam® COLON
      2 Capsule Endoscopy System (CCE) procedures in average risk patients.

      Patients will be randomized to receive one of two bowel preparation regimens prior to PillCam
      CCE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, consecutive, randomized study. Average-risk subjects
      undergoing CCE without optical colonoscopy will be consecutively enrolled and randomized 1:1
      to receive one of two bowel preparation regimens prior to PillCam CCE.

      Subjects will be enrolled at 5-10 clinical sites in the United States. Subjects who meet the
      eligibility criteria will be screened for study participation at a baseline visit and will be
      evaluated on the procedure day or until capsule excretion. A telephone follow-up will be
      conducted 5 to 9 days post-capsule ingestion to verify capsule excretion, assess patient
      well-being, and capture any adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)</measure>
    <time_frame>Within two weeks of study procedure</time_frame>
    <description>The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE</measure>
    <time_frame>an expected average of 3 weeks from study procedure</time_frame>
    <description>Will be assessed from RAPID video in total and by segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE</measure>
    <time_frame>an expected average of 3 weeks from study procedure</time_frame>
    <description>Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE</measure>
    <time_frame>an expected average of 3 weeks from study procedure</time_frame>
    <description>Will be assessed from RAPID video in total and by segment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE</measure>
    <time_frame>an expected average of 3 weeks from study procedure</time_frame>
    <description>Will be assesses by applicable case report form (CRF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE</measure>
    <time_frame>Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.</time_frame>
    <description>Will be assesses by applicable CRF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Colorectal Cancer Screening</condition>
  <arm_group>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PillCam® COLON 2 procedure-CONTROL</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Senna tablets</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUPREP oral sulfate solution</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisacodyl</intervention_name>
    <arm_group_label>Bowel preparation regimen -Control</arm_group_label>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUPREP oral sulfate solution with Gastrografin</intervention_name>
    <arm_group_label>Bowel preparation regimen-Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between 50 and 75 years of age.

          2. Subject is classified as average risk per the American Gastroenterological Association
             Guidelines on Colorectal Cancer Screening: Individuals without a personal or family
             history of colorectal cancer (CRC) or adenomas, inflammatory bowel disease, or
             high-risk genetic syndromes.

          3. Subject is willing and able to participate in the study procedures and to understand
             and sign the informed consent.

        Exclusion Criteria:

          1. Subject with history of polyps (including those identified by computed tomography
             [CT], optical colonoscopy, sigmoidoscopy, etc.).

          2. Subject with history of negative colon assessment (including CT, optical colonoscopy,
             sigmoidoscopy etc.) within 5 years as these subjects would be defined not requiring
             screening in this time frame.

          3. Subject with suspected or diagnosed with hematochezia, melena, iron deficiency with or
             without anemia, or any other rectal bleeding, including positive fecal occult blood
             test of any variety.

          4. Subject with any condition believed to have an increased risk of capsule retention
             such as suspected or known bowel obstruction, stricture, or fistula.

          5. Subject with dysphagia or any swallowing disorder.

          6. Subject with serious medical conditions that would increase the risk associated with
             capsule or colonoscopy that are so severe that screening would have no benefit.

          7. Subject with a cardiac pacemaker or other implanted electromedical device.

          8. Subject expected to undergo MRI examination within 7 days after ingestion of the
             capsule.

          9. Subject with clinical evidence of renal disease, including clinically significant
             laboratory abnormalities of renal function within the past 6 months, or at any time in
             the past if not tested within the last 6 months, defined as creatinine, blood urea
             nitrogen (BUN), and/or glomerular filtration rate (GFR) outside of the local
             laboratory reference range.

         10. Subject with known gastrointestinal motility disorders.

         11. Subject with allergies or known contraindication to the medications or preparation
             agents used in the procedure as described in the relevant instructions for use.

         12. Subject with comorbidities which, in the opinion of the investigator, will not be
             appropriate for the study or the subject has an estimated life expectancy of less than
             6 months.

         13. Subject is considered to be part of a vulnerable population (e.g. prisoners or those
             without sufficient mental capacity).

         14. Subject is pregnant, suspected pregnant, or is actively breast-feeding. Females of
             child-bearing potential will be required to provide either a urine pregnancy test or
             serum pregnancy test as part of the participant's standard of care regardless of their
             participation in the study (except for subjects who are surgically sterile or are
             post-menopausal for at least two years).

         15. Subject has participated in an investigational drug or device research study within 30
             days of enrollment that may interfere with the subject's safety or ability to
             participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas K Rex, Dr.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis Gastroenterology and Hepatology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Gastroenterology</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Gastroenterology, PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <results_first_submitted>March 6, 2016</results_first_submitted>
  <results_first_submitted_qc>May 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>January 22, 2017</last_update_submitted>
  <last_update_submitted_qc>January 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyps</keyword>
  <keyword>Capsule endoscopy</keyword>
  <keyword>Bowel preparation regimen</keyword>
  <keyword>Average risk patients for colorectal cancer screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Bisacodyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bowel Preparation Regimen -Control</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-CONTROL
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
        </group>
        <group group_id="P2">
          <title>Bowel Preparation Regimen-Test</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bowel Preparation Regimen -Control</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-CONTROL
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
        </group>
        <group group_id="B2">
          <title>Bowel Preparation Regimen-Test</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="50" upper_limit="67"/>
                    <measurement group_id="B2" value="53" lower_limit="50" upper_limit="68"/>
                    <measurement group_id="B3" value="53" lower_limit="50" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)</title>
        <description>The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum).</description>
        <time_frame>Within two weeks of study procedure</time_frame>
        <population>this was calculated on the per protocol analysis (PPAS) set excluding patients with one (or more) unseen segment in Cecum, Ascending and Transverse colon.</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen -Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-CONTROL
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)</title>
          <description>The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum).</description>
          <population>this was calculated on the per protocol analysis (PPAS) set excluding patients with one (or more) unseen segment in Cecum, Ascending and Transverse colon.</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum Excellent cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0"/>
                    <measurement group_id="O2" value="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum Good cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum Fair cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum Poor cleansing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE</title>
        <description>Will be assessed from RAPID video in total and by segment</description>
        <time_frame>an expected average of 3 weeks from study procedure</time_frame>
        <population>This analysis is a subset of the PPAs excluding patients with one or more missing video data for Cecum, Ascending and transverse colon. Patients with at least one polyp detected on overall segments.</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen -Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE</title>
          <description>Will be assessed from RAPID video in total and by segment</description>
          <population>This analysis is a subset of the PPAs excluding patients with one or more missing video data for Cecum, Ascending and transverse colon. Patients with at least one polyp detected on overall segments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8"/>
                    <measurement group_id="O2" value="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rectum (any size)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum (polyps ≥6mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cecum Overall (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ascending Overall (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transverse (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum (polyps ≥10mm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE</title>
        <description>Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment</description>
        <time_frame>an expected average of 3 weeks from study procedure</time_frame>
        <population>The following patients were excluded from the analysis:2 withdrawn patients, 1 LTF (Lost to follow-up) patient, 2 pattients with failed prcedure, 16 patients with incomplete COLON exam.</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen - Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure- Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE</title>
          <description>Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment</description>
          <population>The following patients were excluded from the analysis:2 withdrawn patients, 1 LTF (Lost to follow-up) patient, 2 pattients with failed prcedure, 16 patients with incomplete COLON exam.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0.4" upper_limit="7.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE</title>
        <description>Will be assessed from RAPID video in total and by segment</description>
        <time_frame>an expected average of 3 weeks from study procedure</time_frame>
        <population>Per protocol analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen -Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure- Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE</title>
          <description>Will be assessed from RAPID video in total and by segment</description>
          <population>Per protocol analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE</title>
        <description>Will be assesses by applicable case report form (CRF)</description>
        <time_frame>an expected average of 3 weeks from study procedure</time_frame>
        <population>PPAS: Subjects withdrawn prior to the PillCam procedure (3) and subjects with one or more of the following protocol deviations (13) have been excluded: Evening PEG intake &lt;1h and &gt; 2.15h, Morning PEG intake &lt;1h and &gt;2:15 h, Capsule ingestion l&lt;45 min or &gt;75 min after PEG intake , Overall PEG intake volume is less than 3 liters</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen -Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE</title>
          <description>Will be assesses by applicable case report form (CRF)</description>
          <population>PPAS: Subjects withdrawn prior to the PillCam procedure (3) and subjects with one or more of the following protocol deviations (13) have been excluded: Evening PEG intake &lt;1h and &gt; 2.15h, Morning PEG intake &lt;1h and &gt;2:15 h, Capsule ingestion l&lt;45 min or &gt;75 min after PEG intake , Overall PEG intake volume is less than 3 liters</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE</title>
        <description>Will be assesses by applicable CRF</description>
        <time_frame>Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Bowel Preparation Regimen -Control</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
          </group>
          <group group_id="O2">
            <title>Bowel Preparation Regimen-Test</title>
            <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE</title>
          <description>Will be assesses by applicable CRF</description>
          <population>Full analysis set</population>
          <units>percentage of participants with &gt;1 AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected starting from the screening visit and until 5-9 following the PillCam procedure day.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bowel Preparation Regimen -Control</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Control
Senna tablets
PEG
Metoclopramide
Erythromycin
SUPREP oral sulfate solution
Bisacodyl</description>
        </group>
        <group group_id="E2">
          <title>Bowel Preparation Regimen-Test</title>
          <description>Regimen includes administration of:
Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository.
PillCam® COLON 2 procedure-Test
Senna tablets
PEG
Metoclopramide
Erythromycin
Bisacodyl
SUPREP oral sulfate solution with Gastrografin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Sinusitis</sub_title>
                <description>Subject experienced double vision and swollen eye and was hospitalized. He was scheduled to undergo Functional Endonasal sinus surgery.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dyspesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritation</sub_title>
                <description>Skin irritation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <description>Muscle strain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haedache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior written consent is required for PI to independently publish any study results before a multi-center publication is released. If a multi-center manuscript is not submitted for publication within 1 year after completion of the Trial, PI shall have the right to Publish results. Sponsor shall respond within 45 days and shall have the right to delay the Publication for an additional 90.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Liron Bar Yaakov</name_or_title>
      <organization>Given Imaging (a Medtronic company)</organization>
      <phone>+97249097946</phone>
      <email>liron.bar-yaakov@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

